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Summary. Applied researchers are increasingly interested in whether and how treatment effects
vary in randomized evaluations, especially variation not explained by observed covariates. We pro-
pose a model-free approach for testing for the presence of such unexplained variation. To use this
randomization-based approach, we must address the fact that the average treatment effect, generally
the object of interest in randomized experiments, actually acts as a nuisance parameter in this setting.
We explore potential solutions and advocate for a method that guarantees valid tests in finite samples
despite this nuisance. We also show how this method readily extends to testing for heterogeneity be-
yond a given model, which can be useful for assessing the sufficiency of a given scientific theory. We
finally apply our method to the National Head Start Impact Study, a large-scale randomized evaluation
of a Federal preschool program, finding that there is indeed significant unexplained treatment effect
variation.
Keywords: causal inference, randomization test, Head Start, heterogeneous treatment effect
1. Introduction
Researchers and practitioners are increasingly interested in whether and how treatment effects vary
in randomized evaluations. For example, economic theory predicts that changes in welfare policy
will lead to heterogeneous responses beyond those explained by observable characteristics. Given
this, how can we use experimental data to assess whether there is in fact unexplained treatment
variation (Bitler et al., 2010)? Similarly, we might be interested in assessing the effect of scaling
up a promising intervention evaluated on a limited subpopulation (O’Muircheartaigh and Hedges,
2014). If we only use observed characteristics to predict the program’s effectiveness on the new
population, we might wonder if we are missing critical unexplained variation, which could undermine
our generalization. The goal of this paper is to build a framework to assess treatment effect variation
not explained by observed covariates, also known as idiosyncratic variation (e.g., Heckman et al.,
1997; Djebbari and Smith, 2008).
Unfortunately, assessing such variation is difficult—to paraphrase Anna Karenina: “constant
treatment effects are all alike; every varying treatment effect varies in its own way.” In general,
researchers investigating specific types of idiosyncratic variation must therefore rely on strong
modeling assumptions to draw meaningful conclusions from the data (Cox, 1984; Heckman et al.,
1997; Gelman, 2004). The key contribution of our paper is an approach that tests for the presence
of unexplained treatment effect variation without requiring any such modeling assumptions. In
the simplest case, the proposed method is a test of the null hypothesis that the treatment effect is
constant across all units. More generally, the approach tests whether there is significant unexplained
variation beyond a specified model of treatment effect.
Of course, all treatment effects vary in practice, especially in the social sciences, which is our
area of application. The key question is whether the unexplained variation is sufficiently large
to be of substantive importance. As with all omnibus-type testing procedures, rejecting this null
hypothesis does not provide any indication of the source of the unexplained variation. Rather, we
view this procedure as a non-parametric first step in characterizing the results of a randomized
experiment.
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In the simplest no-covariate case, the goal of this approach is to test whether the treatment out-
come distribution is the same as the control outcome distribution shifted by the Average Treatment
Effect (ATE), a constant. Such testing would be straightforward if this shift were known—we could
simply apply standard Kolmogorov-Smirnov-type (KS) tests. However, since the shift is not known,
it is a nuisance parameter that we must estimate. In this case, otherwise sensible methods, such
as “plug-in” approaches, can fail, even asymptotically (e.g., Babu and Rao, 2004). Incorporating
covariates only compounds this problem.
Testing features of distributions in the presence of nuisance parameters has a long history in
statistics and econometrics, where in the latter it is known as the Durbin Problem (Durbin, 1973).
Several papers tackle this issue in the context of comparing treatment and control outcome distri-
butions, appealing to various asymptotic justifications to bypass the nuisance parameter problem.
These include a martingale transformation (Koenker and Xiao, 2002) and subsampling (Cher-
nozhukov and Ferna´ndez-Val, 2005).
We take a different approach, exploiting the act of randomization as the “reasoned basis for
inference” (Fisher, 1935). The corresponding Fisher Randomization Test (FRT) does not rely on
further model assumptions, asymptotics, or regularity conditions (for a review, see Rosenbaum,
2002b). For the constant treatment effect case, when the ATE is assumed known, the FRT proce-
dure yields an exact p-value for the sharp null hypothesis of a constant treatment effect (for one
generalization, see Abadie, 2002). When the ATE is unknown, the null hypothesis is no longer
sharp. To correct for this, we first construct a confidence interval for the ATE, repeat the FRT
procedure pointwise over that interval, and then take the maximum p-value. As Berger and Boos
(1994) show, this procedure guarantees a valid test, despite the presence of the nuisance parameter.
This process readily generalizes for testing treatment effects beyond a hypothesized model.
Our FRT-based approach has several key advantages. First, since the FRT approach is justified
by the physical randomization alone, it yields valid inference in finite samples without relying on
asymptotics or requiring absolutely continuous outcomes. Second, the FRT automatically accounts
for complex experimental designs, such as stratified and matched-pair randomizations or even re-
randomization (Morgan and Rubin, 2012). Third, this procedure is valid for any test statistic,
though some statistics will be more powerful in certain settings. With this flexibility, researchers
can easily extend the FRT approach, tailoring the specific test statistic to their particular problem
of interest.
Using this framework, we assess treatment effect variation in the National Head Start Impact
Study, a large-scale randomized evaluation of Head Start, a Federal preschool program (Puma
et al., 2010). After evaluating a range of null models, we find that there is substantial unexplained
treatment effect variation, even when considering heterogeneity across age of student, dual-language
learner status, and baseline academic skill level, suggesting that policymakers should not base key
decisions on the topline results alone.
The paper proceeds as follows. Section 2 describes treatment effect variation using the potential
outcomes framework as well as how variation depends on the chosen outcome scale. Section 3 gives
an overview of various measures of treatment effect variation. Section 4 outlines the FRT method
we propose, and Section 5 generalizes this approach to incorporate covariates. Sections 6 through
8 provide some simulation studies, apply this approach to Head Start, and discuss next steps. The
on-line supplementary material contains all proofs as well as additional details.
2. Defining Treatment Effect Variation
Following the causal inference literature, we describe our approach using the potential outcomes
framework (Neyman, 1990; Rubin, 1974). We focus on the case of a randomized experiment with a
binary treatment, Zi, and continuous outcome, Yi. Let N be the number of subjects in the study,
with N1 of them randomly assigned to treatment and N0 of them assigned to control. As usual, we
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invoke the Stable Unit Treatment Value Assumption, which states that there is only one version of
the potential outcomes and that there is no interference between subjects (Rubin, 1980).
With this setup, the potential outcomes for subject i under treatment and control are Yi(1)
and Yi(0). The science table is the N × 2 table containing the potential outcomes for all N units
(Rubin, 2005). Each individual’s observed outcome is a function of the treatment assignment and
the potential outcomes,
Y obsi = ZiYi(1) + (1− Zi)Yi(0),
where the randomness comes only from the random treatment assignment. Let Z and Yobs denote
the treatment assignment and observed outcome vectors, respectively. We define the individual
treatment effect in the usual way as τi = Yi(1) − Yi(0), but note that other contrasts are also
possible. Finally, we define the finite sample average treatment effect as:
τ =
1
N
N∑
i=1
Yi(1)− Yi(0).
This is a statement about the N units we observe. In other words, we condition on the sample at
hand.
The treatment effect is constant if τi = τ for all i = 1, . . . , N . Otherwise, we say that the
treatment effect varies across experimental units. In the language of hypothesis testing, we can
define the constant treatment effect null as:
HC0 : Yi(1)− Yi(0) = τ ∀i for some τ. (1)
If τ were known to be τ = τ0, this hypothesis becomes sharp.
2.1. Constant shift
We can not, however, directly observe any individual-level treatment effects, τi, since we only ever
observe one potential outcome for each unit. Instead, we observe the marginal distributions of the
treatment and control groups. Because of this, much of the literature (see, e.g., Cox, 1984) defines
a “constant treatment effect” as a statement that the marginal CDFs of the potential outcomes of
the experimental and control unit distributions F0(y) and F1(y) are a constant shift apart:
H0 : F1(y) = F0(y − τ) for some τ. (2)
Rejecting H0 implies rejecting the more restrictive null H
C
0 that τi = τ for all i, but rejecting
HC0 does not necessarily imply rejecting H0. That said, it is difficult to imagine the practical
situation in which there is a substantial, varying treatment effect that nonetheless yields parallel
CDFs. Even more interestingly, the two nulls appear to be indistinguishable given observed data.
Therefore, while not formally correct, we generally view tests for HC0 as tests for H0. Simulation
studies, not shown, suggest that this practice generally leads to valid, if somewhat conservative,
tests. Understanding this relationship is an important area of future work, and is closely related
to the interplay between Neyman- and Fisher-style tests. See, for example, Ding (2014).
2.2. Treatment effect variation and scaling
Whether a given treatment effect is constant critically depends on the scale of the outcomes. For
example, a job training program that has a constant effect in earnings does not have a constant
effect in log-earnings. This scaling issue is a particularly salient issue if the outcome is, say, test
scores in an educational context where scale is not necessarily well defined.
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Cox (1984) demonstrates the importance of scaling in a special case first explored by G.E.H.
Reuter: if the marginal CDFs of Y (1) and Y (0) do not cross, there exists a monotone transformation
such that the distributions of the transformed treatment and control outcomes are a constant shift
apart. Unfortunately, G.E.H. Reuter has since passed away and his proof is lost to the literature;
we provide a proof of this theorem in the supplementary material.
Theorem 1. Assume F1(·) and F0(·) are both continuous and strictly increasing CDFs
of the marginal distributions of Y (1) and Y (0), respectively, with strict stochastic dominance
F1(y) < F0(y) for all y on [F
−1
0 (0), F
−1
1 (1)]. There exists an increasing monotone transformation
g such that the CDFs of g{Y (1)} and g{Y (0)} are parallel.
While the applicability of this result is limited to non-crossing CDFs, it nonetheless emphasizes
the importance of scale and of understanding the problem at hand. In general, whether a given
transformation is substantively reasonable depends on the context: a cube-root transformation
might be very sensible if the outcome is in cm3, but not if the outcome is in dollars (Berrington de
Gonza´lez and Cox, 2007).
3. Measures of Treatment Effect Variation
There are many approaches to measuring treatment effect variation, dating back to early work
on non-additivity in randomized experiments (see Berrington de Gonza´lez and Cox, 2007). We
briefly highlight three basic measures: comparing marginal variances, comparing marginal CDFs,
and comparing marginal quantiles. The usual testing procedures with the measures discussed
here typically yield reasonable inference only when particular conditions, such as Normality or
asymptotic regularity, are met. In the next section, we show how the Fisher Randomization Test
can yield exact p-values with any of these test statistics, regardless of whether these conditions are
met.
To fix notation, assume that the potential outcome for treatment z is drawn from the distribution
of Y (z), with marginal PDF fz(y), CDF Fz(y), quantile function F
−1
z (q), mean µz, and variance
σ2z . Sample analogues are denoted with hats.
3.1. Comparing variances
Following Cox (1984), we can assess treatment effect heterogeneity by examining the marginal
variances of the treatment and control outcomes. In particular, if the treatment effect is constant,
Yi(1) = Yi(0) + τ and var{Yi(1)} = var{Yi(0)}. Therefore, unequal sample variances imply treat-
ment effect heterogeneity, although the converse is not necessarily true. This makes the variance
ratio,
tvar =
σ̂21
σ̂20
,
an attractive statistic, especially if the researcher believes that the treatment plausibly induces
greater variance (e.g., Gelman, 2004).
Furthermore, if the marginal distributions of potential outcomes are Normal, then tvar follows
an F distribution and the corresponding test is the Uniformly Most Powerful test of equal variance.
However, as we show in the supplementary material, the F test is highly sensitive to departures
from Normality, even asymptotically. We also provide a test that uses higher-order moments, such
as kurtosis, to improve inference in this case.
3.2. Comparing CDFs
In general, second-order moments might not capture some important features of heterogeneity,
especially when τi varies with Yi(0). For example, a classroom intervention might have the largest
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effect on the lowest performing students. An alternative approach compares marginal CDFs rather
than higher-order moments, suggesting the use of a KS-like test to compare the treatment and
control groups. The classic KS statistic, which measures the maximum point-wise distance between
two curves, is tKS = maxy |F̂1(y) − F̂0(y)|. This test, however, could reject if the treatment effect
is constant but non-zero, since it is an omnibus test for any difference in distribution.
To focus on heterogeneous treatment effects, we want to shift one of the CDFs by the ATE, and
then compare the resulting distributions. In particular, if τ were known, we could calculate:
tKS(τ) = max
y
∣∣∣F̂0(y)− F̂1(y + τ)∣∣∣ .
Under the null, the two aligned CDFs should be the same and we can directly compare the observed
test statistic to the null distribution for the classic, non-parametric distribution-free KS test.
In practice, τ is unknown and is therefore a nuisance parameter. One natural approach is to
plug in the difference-in-means estimate, τ̂ = µ̂1 − µ̂0, yielding the “shifted” KS (SKS) statistic:
tSKS = max
y
∣∣∣F̂0(y)− F̂1(y + τ̂)∣∣∣ .
As we prove in the supplementary material, however, comparing this test statistic to the usual null
KS distribution yields invalid p-values. In particular, tSKS converges to an asymptotic distribution
that depends on the underlying distributions of the outcomes.
3.3. Comparing quantiles
A third approach focuses on quantiles rather than on CDFs. In this formulation,
F−11 (q) = F
−1
0 (q) + τ(q),
where τ(q) is the quantile process for the treatment effect. If the effect is constant, then τ(q) is
constant across q. Based on this, Chernozhukov and Ferna´ndez-Val (2005) propose a class of test
statistics based on the estimated quantile process,
tQP =
∥∥τ̂(q)− τ̂∥∥,
where τ̂(q) is an estimate of the treatment effect at the qth quantile, and ‖ · ‖ is some norm, such
as sup.
As in the CDF case, τ remains a nuisance parameter, so the Durbin problem remains. Cher-
nozhukov and Ferna´ndez-Val (2005) solve this via subsampling. Their main argument is that, under
some regularity conditions, a particular form of re-centered subsampling can yield asymptotically
valid tests for whether τ(q) is constant, despite dependence on τ̂ . Chernozhukov and Ferna´ndez-Val
(2005) and Linton et al. (2005) also propose a bootstrap variant of the subsampling procedure,
though the bootstrap does not have the same general, theoretical guarantees as subsampling. For
other approaches for inference on quantiles, see Doksum and Sievers (1976), Rosenbaum (1999),
and Koenker and Xiao (2002).
4. A Randomization Test for Treatment Effect Variation
Our analytic approach is based on the FRT. To perform an FRT, a researcher needs three main
ingredients: a randomized treatment assignment mechanism, a sharp null hypothesis, and a test
statistic, t(Z,Yobs), such as those in the previous section. Under the sharp null, all missing poten-
tial outcomes can be imputed and are thus known. Given all the potential outcomes, a researcher
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can then enumerate the possible values of a specified test statistic under all possible randomiza-
tions. This enumeration forms the exact null distribution, called the reference distribution, of that
statistic.
4.1. FRT with known τ
First consider a sharp null hypothesis of no heterogeneity for a known τ :
Hτ0 : Yi(1) = Yi(0) + τ ∀i.
Given this null, we can immediately impute all missing potential outcomes from the observed data.
For a unit with Zi = 1, the potential outcome under treatment is Y
obs
i and the potential outcome
under control is Y obsi −τ . For a unit with Zi = 0, the potential outcome under treatment is Y obsi −τ
and the potential outcome under control is Y obsi .
The steps of the FRT are then:
(a) Calculate the test statistic for the observed data, t = t(Z,Yobs).
(b) Given the observed outcomes, Y obsi , the treatment assignment, Zi, and the sharp null, H
τ
0 ,
generate the corresponding science table.
(c) Enumerate all possible treatment assignments, Z˜, under the given treatment assignment mech-
anism. These are all possible treatment assignments that we could have observed for a given
experiment. Typically, there are too many possible enumerations so we instead take a random
sample from the set of all possible assignment vectors.
(d) For each possible assignment, Z˜, compute: (1) the observed outcomes, Y˜obs given Z˜ and the
science table; and (2) the test statistic t˜ = t(Z˜, Y˜obs). The resulting distribution of t˜ across
all randomizations is the exact distribution of the test statistic given the units in the sample
and the null hypothesis.
(e) Compare the observed statistic t to its null distribution and obtain the p-value
p(τ) ≡ Pr ( t ≥ t˜ ) .
This procedure yields an exact test for any test statistic assuming τ is known. For instance, we can
use as test statistics any of the measures of treatment effect heterogeneity discussed in the previous
section, such as tvar, tSKS and tQP .
4.2. FRT with unknown τ
When τ is unknown, the null hypothesis is no longer “sharp” in the sense that we can no longer
impute all the missing potential outcomes. We provide two options.
4.2.1. FRT plug-in method (FRT-PI)
One option is to impute the science table with the estimated τ̂ instead of τ , and run the FRT to
obtain the distribution of t for that table. Ideally, if τ̂ is close to τ , the resulting science tables will
be close in that the exact reference distribution for the imputed science table should look similar to
the true reference distribution for our sample. If this is the case, then inference from this plug-in
procedure should be close to the case where τ is known, i.e., p(τ̂) ≈ p(τ). Nonetheless, as Berger
and Boos (1994) discuss, there are no general theoretical guarantees from such a procedure. In
fact, as we show in the simulation studies, this approach can lead to invalid results when τ̂ is
highly variable, such as for skewed distributions, though it does appear to have sensible size for
approximately Normal outcomes.
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Nevertheless, this approach is distinct from appealing to the asymptotic distribution of a given
test statistic. Instead, this attempts to generate a reference distribution based on the data at hand,
which may make the Durbin problem far less severe. Even so, as we show next, we can guarantee
validity with a mild extension of this approach.
4.2.2. FRT confidence interval method (FRT-CI)
An alternative approach is to find the maximum p-value across all values of the nuisance parameter,
τ ′ ∈ (−∞,∞):
psup = sup
τ ′
p(τ ′)
where p(τ ′) is obtained by performing an FRT under the sharp null Hτ ′0 . Although psup is conser-
vative, it is still valid since Pr(psup ≤ α) ≤ Pr(p(τ) ≤ α) ≤ α. This approach, however, leads to two
complications in practice: (1) maximizing a quantity over the entire real line is computationally
intractable; and (2) doing so can lead to a dramatic loss in statistical power.
Berger and Boos (1994) propose a convenient fix to these issues—rather than maximize over the
entire real line, they instead maximize over a (1− γ)-level confidence interval for τ , CIγ :
pγ = sup
τ ′∈CIγ
p(τ ′) + γ.
Following Rosenbaum (2002b), we could obtain an exact (under HC0 ) confidence interval, CIγ ,
by inverting FRTs for a sequence of sharp null hypotheses, Yi(1) − Yi(0) = τ ′. In practice, we
approximate this confidence interval based on the Neyman variance estimator (Neyman, 1990).
The following proposition guarantees the validity of the resulting p-value.
Proposition 1. Given that CIγ is a (1−γ)-level confidence interval for τ , pγ is a valid p-value,
in the sense that Pr(pγ ≤ α) ≤ α under the null.
As Berger and Boos (1994) note, the behavior of the p-values at the tails of the nuisance parameter
interval can be complex and, unsurprisingly, depends on both the specific test statistic and the
value of the nuisance parameter. For example, they might climb or be driven to zero. While we
cannot provide theoretical guarantees, in our experience, the p-values for our chosen test statistics,
tSKS , tend toward 0 or remain flat for values of τ
′ moderately far from τ , which suggests our
method does not sacrifice much in terms of power.
To illustrate this procedure, we simulate a balanced randomized experiment with a constant
treatment effect, N = 200, Yi(0)
iid∼ Exponential(1), and Yi(1) = Yi(0) + 2. Figure 1 shows p-
values from FRTs for a fixed data set under Hτ
′
0 for τ
′ in a 99.9% confidence interval, following
the procedure described above using tSKS as the test statistic. If the true τ were known, we could
obtain the exact p-value of p = 0.16. The p-value at the observed value of τ̂ is too low, around
p = 0.09, demonstrating why a simple plug-in approach may yield incorrect size. Finally, taking
the maximum p-value over the 99.9% Confidence Interval yields a p-value of p = 0.17, only slightly
larger than the true value of 0.16. This figure, with the “mountain” shape, is typical for this test
statistic under many data generation processes.
5. Incorporating Covariates
In practice, we typically observe a vector of individual-level pre-treatment covariates, X, that are
possibly related to the outcome. This can help increase the power of our test and also enable
exploration of variation beyond that which can be explained by X.
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Fig. 1. p-values over the range of the nuisance parameter. The rug indicates the grid of sampled τ . Vertical
dotted lines indicate bounds of 99.9% confidence interval CIγ on τ . Horizontal lines indicate p-values from,
bottom to top, plugging in τ̂ , using the known τ , and maximizing the p-value over CIγ .
5.1. Using covariates to improve power
To improve power we allow the chosen test statistic to account for the relationship between the
covariates and outcome, such as via a linear regression of outcome on covariates and treatment with
no interaction. In the linear regression case, for example, we can generate a “regression adjusted
KS statistic.” This statistic compares the CDFs of the residuals of a regression of Y on X and Z
(with no interaction of X and Z). Let êi = Y
obs
i − Ŷi be the residuals of a pre-specified regression,
with Ŷi being the associated predicted values. Then define our test statistic as
tRKS = max
y
∣∣∣F̂e1(y)− F̂e0(y)∣∣∣ (3)
where F̂e1(y) and F̂e0(y) are the empirical CDFs of the residuals êi for the treatment and control
groups, respectively.
To motivate this, consider the simple regression of Y on Z. The residuals of this regression are
êi = Y
obs
i − µ̂1 for the treated units and êi = Y obsi − µ̂0 for the control units. Since τ̂ = µ̂1− µ̂0 and
F̂0(y) − F̂1(y + τ̂) = F̂0(y − µ̂0) − F̂1(y − µ̂1), the regression-adjusted KS statistic for the simple
regression of Y on Z is equivalent to the Shifted KS statistic: without covariates, tSKS = tRKS .
Now, by including covariates we hope to remove variation due to covariates, making variation
in treatment effect more readily apparent. As long as X is predictive of Y , regression adjustment
reduces residual variation in the marginal outcomes, but cannot directly reduce variation in the
treatment effect. In general, covariate adjustment will therefore yield more powerful test statistics.
Importantly, since the validity of the approach is justified by randomization alone, this adjustment
does not require any underlying model assumptions. This approach is analogous to the classical,
model-assisted covariate adjustment in randomized experiments (Rosenbaum, 2002a; Lin, 2013).
We can easily repeat this approach with tvar, re-defining the test statistic via the residual
variance after a regression of Y on X. However, accounting for covariates with quantile-based
statistics is more complicated, with two basic approaches in the literature. In the conditional
approach, we re-define tQP via the estimate of τ(q) in a quantile regression of Y on both X and Z,
as in Koenker and Xiao (2002). In the unconditional approach, we re-define tQP via the estimate
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of τ(q) in a weighted quantile regression of Y on Z, with weights defined as a given function of X,
as in Firpo (2007) or Firpo et al. (2009).
5.2. Treatment effect variation beyond covariates
In many applications, the constant treatment effect null may be of limited scientific interest. In-
stead, we wish to investigate whether there is significant treatment effect variation beyond a par-
ticular model for the treatment. For example, Bitler et al. (2010) propose the Constant Treatment
Effect Within Subgroups model, which assumes that the average treatment effect differs across
observable subgroups (e.g., by education or age group) but is otherwise constant within those
subgroups.
To make this more precise, let W be an n×(k+1) matrix of the unit vector and k pre-treatment
covariates. The unit vector corresponds to the overall average treatment effect and the covariates
allow for modeled treatment effect heterogeneity. We then replace the null hypothesis of a constant
treatment effect with the assumption that the individual-level treatment effects are a particular
function of W:
HW0 : Yi(1)− Yi(0) = β>Wi ∀i for some β, (4)
where β is some (unknown) vector of coefficients for W. Under the null, there is some β such that
the set of Yi(1)− β>Wi yields the same CDF as the set of Yi(0).
We can easily test this hypothesis using the regression-adjusted KS statistic, tRKS , constructed
via the residuals of a regression of Y on W, Z, and W×Z. This regression yields point estimates
β̂ with a corresponding (k + 1)-dimensional (100 − γ)% confidence region. To obtain the FRT-PI
p-value, we simply use the science table based on β̂. To obtain the FRT-CI p-value, we must repeat
the FRT procedure for each point in a potentially high-dimensional grid. We defer a detailed
discussion of the estimation issues in this setting to our companion paper.
We can also extend this regression approach to account for covariates that are not assumed to
interact with the treatment (i.e., those in X but not W). Furthermore, we can allow the treatment
effect model to be arbitrarily flexible, including series expansions on the covariates, such as splines
or higher-order polynomials. See Crump et al. (2008) for a discussion of non-parametric estimation
in this context.
5.3. Subgroup variation
We briefly turn to the special case in which the treatment effect is assumed to vary across discrete
groups. Let Y obsik be the observed outcome of unit i in group k, for i = 1, · · · , nk and k = 1, · · · ,K,
with n1k the number of treated units in group k.
For example, consider a stratified experiment, where both nk and n1k are fixed. Of course,
we can always analyze a stratified experiment as if it were K separate, completely randomized
experiments. However, we can also test whether variation across strata explains the full variation
in treatment effects. This corresponds to the following joint null hypothesis of stratum-specific
treatment effects, T ≡ (τ1, . . . , τK):
H joint0 : Yik(1) = Yik(0) + τk ∀ i, ∀ k, for some T .
Under this null, the pooled CDF of the recentered-by-stratum outcomes of all the units under
treatment (i.e., the residuals from outcome regressed on strata) would be the same as for control.
To test the null, we then need a measure of discrepancy between the estimates of the two CDFs
as our test statistic. Several choices are possible. First, we can use tRKS , the regression-based test
statistic above, letting W be a matrix of indicators for stratum membership and β be T (with no
intercept). However, if the proportions of treated units differ across strata or if homoskedasticity
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Fig. 2. p-values over the region of the nuisance parameters. The p-values due to the maximum, the plug-in,
and the oracle truth are all marked on the plot. The dotted circle denotes the 1−γ confidence region for the
nuisance parameters.
is implausible, pooling may not be appropriate. Instead, we can post-stratify by weighting each
group-by-stratum empirical CDF with weight proportional to the stratum size. The revised F̂ez is
then
F̂ez(y) =
K∑
k=1
nk
n
F̂ekz(y)
where F̂ekz(y) is the empirical CDFs of the Y
obs
ik − µ̂kz for those units in stratum k with Zi = z.
Similarly, we might instead take a weighted average of individual stratum-level test statistics as
tWSKS =
K∑
k=1
nk
n
tSKS,k.
Figure 2 demonstrates this last approach by extending the results from Figure 1 into two dimensions.
Here we have two distinct subgroups, one of 75 units and one of 375 units, and simulate a balanced
randomized experiment with a treatment effect that is constant within each subgroup, but not
constant overall. The baseline distributions are exponential. We then test for treatment effect
heterogeneity beyond these discrete subgroups. To do this we search over a confidence set, depicted
in the figure, for a maximum p-value. We again see the “mountain shape” and end up with a final p-
value of 0.46, versus p = 0.43 for known τ and p = 0.39 for the plug-in τ̂ . As in the one-dimensional
case, the plug-in p-value is lower than the true p-value. Moreover, the maximum p-value is only
modestly higher than the truth, as the p-values fall away at moderate distances from the true τ .
This plot is typical over several simulation settings. Finally, as expected, if we do an omnibus test
for heterogeneity beyond a single average treatment effect, we reject with p < 0.005. Our model of
constant treatment effect within groups is thus significantly better than a single average, and we
have no evidence for needing a more complex model.
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The Constant Treatment Effect Within Subgroups model of Bitler et al. (2010) is equivalent
to H joint0 except that the number of treated units in each group, nk1, is possibly random rather
than fixed. Here simply conditioning on the observed nk1 for each group (i.e., only considering
randomizations that maintain the nk) and performing the analysis as above yields valid inference.
This is a conditional randomization test, the analogue of post-stratification for testing rather than
estimation (see, e.g., Holt and Smith, 1979; Miratrix et al., 2013).
6. Simulation Studies
We now turn to a series of simulation studies that confirm the validity of the FRT approach and
assess power under a range of plausible scenarios.
6.1. Validity results
First, we examine the different methods under the null hypothesis of a constant treatment effect.
To assess validity, we repeat the following 5000 times each for a given test statistic and underlying
distribution:
(a) generate a sample from the underlying distribution, assuming a constant treatment effect;
(b) randomly assign treatment and obtain observed outcomes;
(c) calculate our test statistic tSKS ; and finally
(d) calculate a p-value using each of several different approaches described below.
We assess five methods:
• Naive Plug-In: This method calculates the usual KS p-value, assuming that the estimated
treatment effect is in fact the true treatment effect.
• FRT-PI and FRT-CI: These methods are the two FRT-based approaches discussed above.
For this simulation, we use a 99.9% confidence interval for τ̂ (i.e., γ = 0.001).
• Subsampling: This method is the subsampling approach of Chernozhukov and Ferna´ndez-Val
(2005), with the authors’ recommended subsampling size of b = 20 + n1/4.
• Bootstrap: This method is based on the bootstrap proposed by Chernozhukov and Ferna´ndez-
Val (2005) and Linton et al. (2005), using the tSKS test statistics. To generate the bootstrap
distribution, we de-mean the treatment and control groups and sample with replacement from
the pooled vector of residuals, keeping the number of treatment and control units fixed.
We assess these five methods for the following distributions: standard Normal, t5, standard Expo-
nential, and Log-Normal, each with a constant treatment effect of +1 unit.
Table 1 shows the rejection rates for a test of size α = 0.05 for each method and Data Generating
Process (DGP). As expected, the naive plug-in approach fails dramatically, either yielding hyper-
conservative or highly invalid size. The FRT-PI approach appears to work well for the symmetric
Normal and t5 distributions, but leads to invalid size for the skewed Exponential and Log-Normal
distributions. The FRT-CI approach corrects for this, yielding exact or conservative size for all
DGPs assessed here, where conservative indicates lower than nominal rejection rates. It is encour-
aging that, even when the FRT-CI is conservative, it is not dramatically so, suggesting we are
not giving up too much power due to the maximization procedure. Subsampling yields correct,
if slightly conservative, rejection rates overall. Finally, the bootstrap approach is invalid for the
Normal, t5, and Exponential distributions.
The bootstrap approach we used seemed the most promising choice. Other alternatives to the
bootstrap exist, but they seem to perform even more poorly. For example, one seemingly obvious
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Table 1. Size of α = 0.05 tests, in percentage points, for different methods under
HC0 . Estimates are based on 5,000 replications, which implies a simulation standard
error of approximately 0.3pp.
Normal t5 Expo Log-Normal
n = 100 1,000 100 1,000 100 1,000 100 1,000
FRT-PI 4.5 5.1 5.4 5.2 11.3 7.7 15.1 7.0
FRT-CI 1.9 3.8 2.1 3.7 4.1 4.9 4.5 5.0
Subsampling 2.3 4.6 1.5 1.6 2.1 2.3 1.1 0.7
Bootstrap 9.3 8.8 7.4 8.3 6.3 6.1 5.0 6.5
Naive Plug-In 0.0 0.0 0.0 0.0 12.3 21.4 36.2 44.7
bootstrap is to repeatedly sample, with replacement, N1 treatment cases and N0 control cases from
their respective original samples, calculating the resulting test statistic. Ideally, this would capture
the variability of the entire process, giving a valid p-value for the actual observed test statistic.
Unfortunately, even if the null were true, the bootstrap null would generally not be in this context,
and so we would end up simulating our distribution under a “near alternative” which gives poor
size. We confirmed this intuition with simulations, not shown in this paper, that indeed show this
approach can fail catastrophically.
6.2. General power simulations
To assess the power of these methods under select alternatives we mirror a set of simulation studies
conducted by both Koenker and Xiao (2002) and Chernozhukov and Ferna´ndez-Val (2005). For
these simulations, we repeatedly generate data with different levels of treatment effect heterogeneity,
denoted by στ , and estimate the probability that a method would reject the null of constant
treatment effect (at α = 0.05) given draws of data and random treatment assignment. Since the
bootstrap, FRT-PI, and naive plug-in are invalid tests, we do not include them here.
We use a binary version of the DGP from Chernozhukov and Ferna´ndez-Val (2005):
Yi(0) = εi, τi = 1 + στYi(0).
with εi ∼ N(0, 1). This model can also be expressed as the classic additive treatment effect model
under Normality, Yi(1) = Yi(0) + τi, where Yi(0) ∼ N(0, 1); τi ∼ N
(
1, σ2τ
)
on the margin, and
στ = 0 corresponds to a constant treatment effect. Note that, as Cox (1984) observes, the F -test
is the Uniformly Most Powerful Test in this setting.
We then extend the simulations from Chernozhukov and Ferna´ndez-Val (2005) by imposing
Log-Normality rather than Normality. In particular, we assume a treatment effect of the following
form:
log Yi(0) = εi, τi = 1 + στYi(0).
Then marginally Yi(1) ∼ Log-Normal {log(στ + 1), 1}+ 1. In either case, for στ > 0, the treatment
effect increases with Yi(0), which is non-negative. Rosenbaum (1999) calls this kind of treatment
effect variation a dilated effect.
Table 2 shows the main power results. For Normal outcomes, both the FRT-CI and subsampling
methods have correct size when στ = 0. However, subsampling appears to be more powerful for
στ > 0, perhaps because the the asymptotics to “kick in” quickly under Normality. For Log-Normal
outcomes, however, the situation is reversed, with much greater rejection rates under FRT-CI than
under subsampling.
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Table 2. Rejection rates for α = 0.05 tests, in percentage points, under se-
lect alternative hypotheses with different levels of treatment effect variation,
στ , and DGPs. Estimates are based on 5, 000 replications, which imply a
simulation standard error of approximately 0.3pp.
FRT-CI Subsampling
στ = 0 στ = 0.2 στ = 0.5 στ = 0 στ = 0.2 στ = 0.5
A. NORMAL OUTCOMES
N = 100 2.3 5.5 23.1 2.4 8.4 39.2
N = 400 3.5 24.8 93.0 4.0 40.1 98.4
N = 800 3.5 52.3 100.0 4.6 72.9 100.0
B. LOG-NORMAL OUTCOMES
N = 100 4.7 7.3 19.3 1.2 2.2 5.9
N = 400 4.7 19.8 70.5 0.6 3.4 32.9
N = 800 4.6 35.1 94.1 0.8 9.1 70.7
7. Application to the Head Start Impact Study
Initially launched in 1965, Head Start is the largest Federal preschool program today, serving around
900,000 children each year at a cost of roughly $8 billion. The National Head Start Impact Study
(HSIS) is the first major randomized evaluation of the program (Puma et al., 2010). The published
report found that, on average, providing children and their families with the opportunity to enroll
in Head Start improved children’s key cognitive and social-emotional outcomes. The report also
included average treatment effect estimates for a variety of subgroups of interest, though there is
only significant impact variation across a small number of the reported, pre-treatment covariates.
After these findings were released, many researchers argued that the reported topline results
masked critical variation in program impacts. For example, Bitler et al. (2013) show that the
treatment is differentially effective across quantiles of the test score distribution; Bloom and Weiland
(2014) explore variation in program impacts across select subgroups and across the 351 Head Start
centers in the study; and Feller et al. (2014) investigate differential effects based on the setting of
care each child would have received in the alternative treatment condition.
All of these approaches, however, estimate treatment effect variation by relying on a specific
set of models, such as quantile or hierarchical regression. Given the breadth of research in this
area, a natural question is whether the topline and subgroup average treatment effects for HSIS
are indeed sufficient summaries of the program’s effect. We investigate this question by focusing on
the Peabody Picture Vocabulary Test (PPVT), a widely used measure of cognitive ability in early
childhood. We also utilize a rich set of pre-treatment covariates, including pre-test score, child’s
age, child’s race, mother’s education level, and mother’s marital status. In addition, we follow the
experimental design and ensure that the randomizations used in the FRT procedure are stratified
by Head Start center. For the sake of exposition, we restrict our analysis to a complete-case subset
of HSIS, with N1 = 2,238 in the treatment group and N0 = 1,348 in the control group. Note that
this restriction could lead to a range of inferential issues which we do not explore here; see Feller
et al. (2014) for a detailed discussion.
As shown in Table 3, we apply the FRT procedure to a set of increasingly flexible null hypothe-
ses. The least flexible models, Model 1 and 2, assesses the null hypothesis of constant treatment
effect across all units without and with covariate adjustment, using the tSKS statistic and the
tRKS statistic respectively. Model 3 adjusts for pre-treatment covariates and allows the treatment
effect to vary by child’s age (three vs. four years old). The most flexible model, Model 4, allows
the treatment effect to vary by child’s age, child’s Dual-Language Learner (DLL) status, and an
indicator for whether the child was in the bottom quartile on an assessment of pre-academic skills
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Table 3. FRT p-values for the Head Start Impact Study, based on
2,000 repetitions. Models (1) and (2) correspond to a null hypothesis of
constant treatment effect. Models (3) and (4) allow the treatment effect
to vary across given covariates.
(1) (2) (3) (4)
p-value: 0.033 0.005 0.005 0.003
Treatment effect varies by: — — age
age
DLL status
acad. skills
Control for covariates: — X X X
prior to the study. The resulting p-values are roughly p = 0.03 for the model without covariates
and p < 0.01 across all three models that adjust for covariates, clearly demonstrating significant
unexplained variation regardless of the exact specification. This provides evidence that there is
indeed substantial treatment effect variation beyond that explained by these subgroups.
8. Discussion
Researchers are increasingly interested in assessing treatment effect heterogeneity. We propose a
framework to unify and generalize some existing statistical procedures for inference about such
variation, using randomization as the “reasoned basis for inference” for the testing procedure. As
a result, the method does not rely on any further model assumptions, asymptotics, or regularity
conditions. We use simulation studies to confirm that this approach yields valid results in finite
samples and that its power is competitive with some existing approaches, especially subsampling.
Finally, we apply this method to the National Head Start Impact Study, a large-scale randomized
evaluation, and find that there is indeed significant unexplained treatment variation.
Other randomization-based approaches to heterogeneity also exist. These methods typically
specify a model for heterogeneity and test based on that model. For example Rosenbaum (2011) pro-
vides randomization tests for rare but substantial effects. Rosenbaum (1999) proposes a randomization-
based procedure for non-negative and non-decreasing quantile treatment effects under the assump-
tion of rank preservation. See section 2.4.4 of Rosenbaum (2010) for discussion of testing general
null hypotheses of non-zero treatment effects. By contrast, we attempt to test for heterogeneity in
an unstructured way, though the choice of test statistic is motivated by the problem at hand. As
additional assumptions on the structure of the heterogeneity will increase statistical power, using
these approaches may be more appropriate than our omnibus method when such assumptions are
met.
There is one important complication that we do not directly address here: the case of discrete
outcomes. Even though the FRT procedure still yields valid inference in this setting, the constant
treatment effect hypothesis may no longer be of scientific interest. This is a fundamental issue
and is not specific to any particular testing procedure. For example, consider a semi-continuous
outcome distribution, with a large point mass at zero. For example, in the Connecticut Jobs First
evaluation, roughly half the sample has no earnings (Bitler et al., 2006). Here, the constant effect
null hypothesis implies that welfare reform has the same dollar impact regardless of whether the
individual starts with zero earnings, which is nonsensical. In future work, we hope to explore
different approaches for this setting, including latent variable formulations.
In the end, our approach offers a flexible framework for assessing treatment effect variation in
randomized experiments, allowing researchers to incorporate a broad range of test statistics and
accommodate complex experimental designs. Most of all, our goal is to give applied researchers
a set of tools so that inference about treatment effect variation can becomes standard step in the
analysis of randomized experiments. Next steps are to explore the role of covariates in treatment
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effect variation and, in particular, the interplay between systematic and idiosyncratic treatment
effect variation.
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Supplementary Materials for
“Randomization Inference for Treatment Effect Variation”
The supplementary materials contain four sections and a few additional notes. Section A.1
discusses the importance of scaling in treatment effect variation, and provides a “lost proof” of
Reuter’s Theorem (Cox, 1984). Section A.2 discusses the asymptotic distribution of the variance
ratio statistic for non-Normal outcomes and provides a distribution-free test. Section A.3 explains
why the simple plug-in approach using the KS test fails, even asymptotically. Section A.4 gives a
proof for Proposition 1 in the main text.
A.1. Reuter’s Theorem
As mentioned in Section 2 of the main text, whether a given treatment effect is constant depends
on the scale of the outcomes. In particular, if the marginal CDFs of Y (1) and Y (0) do not cross,
there exists a monotone transformation such that distributions of the transformed treatment and
control outcomes are a constant shift apart as defined by H0 (i.e., we can make the CDFs of the
treatment outcomes and control outcomes parallel). This was first observed by Cox (1984), citing
a theorem due to G. E. H. Reuter. Unfortunately, Reuter has since passed away and his proof has
been lost to the literature. We therefore provide a proof of this theorem here. For convenience we
restate the theorem:
Theorem 2. Assume F1(·) and F0(·) are both continuous and strictly increasing CDFs
of the marginal distributions of Y (1) and Y (0), respectively, with strict stochastic dominance
F1(y) < F0(y) for all y on [F
−1
0 (0), F
−1
1 (1)]. There exists an increasing monotone transformation
g such that the CDFs of g{Y (1)} and g{Y (0)} are parallel.
First, note that stochastic dominance occurs if and only if the CDFs do not cross, hence the
statement of the theorem above. Next, assuming no ties, the finite sample analogue, or the analog
conditioning on the realized sample, is immediate. To prove the theorem we first need a few lemmas.
Lemma 1. Assume that v(u) is a strictly increasing and continuous function defined on [0, 1],
which satisfies v(u) < u for all u. Then there exists a monotone increasing transformation h(·)
such that h(u)− h{v(u)} is a constant for all u ∈ [0, 1].
Proof of Lemma A.1. Define v(1)(u) = v(u) and v(n)(u) = v{v(n−1)(u)} for n ≥ 2; further-
more, define v(−1)(x) = v−1(x) and v(−n)(x) = v−1{v(−(n−1))(x)} for n ≥ 2.
For the trivial case with v(1) < 0, we can easily rescale the range of v(x) to make it parallel to
x because the range is entirely below 0. To do so, define h(·) as follows:
h(x) =
{
x if x > v(1),
v−1(x)− {1− v(1)} if x ≤ v(1).
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Therefore, we have h(u) − h{v(u)} = u − v−1{v(u)} + {1 − v(1)} = 1 − v(1) for all u. Note that
h(u) = u for all our x ∈ [0, 1] so h only impacts the h{v(u)} term in the difference.
For the case with v(1) ≥ 0, we first need to show that there exist an M , such that v(n)(1) ≥ 0
for all n < M and v(M)(1) < 0. We use a proof by contradiction, and assume v(n)(1) ≥ 0 for
all n. A quick induction shows that, since v(1) < 1 and v(n+1)(u) = v{v(n)(u)} < v(n)(u), the
sequence v(n)(1) is strictly decreasing. Furthermore, because the sequence is bounded below by
0, it must have a limit, u0, on [0, 1]. Taking n → ∞ on both sides of v(n)(u) = v{v(n−1)(u)}, we
have u0 = v(u0) < u0, which is impossible. Therefore, such an M indeed exists. We also have
v(0) ≤ v(M)(1) from taking v on both sides of 0 ≤ v(M−1)(1), and we can therefore partition the
real line R as follows:
R =
(
−∞, v(M)(1)
]
∪
(
v(M)(1), v(M−1)(1)
]
∪ · · · ∪
(
v(2)(1), v(1)
]
∪ (v(1),∞) .
We will define h(·) on each piece of the partition above, from the right to the left.
First define h(x) = x within (v(1),∞), and h(x) = v−1(x) − {1 − v(1)} within (v(2)(1), v(1)].
This way of construction guarantees that, for any u ∈ (v(1), 1],
h(u)− h{v(u)} = u− v−1{v(u)}+ {1− v(1)} = 1− v(1).
Next define h(x) = v(−2)(x)− 2{1− v(1)} within (v(3)(1), v(2)(1)] giving, for all u ∈ (v(2)(1), v(1)],
h(u)− h{v(u)} = [v−1(u)− {1− v(1)}]− [v−2{v(u)} − 2{1− v(1)}] = 1− v(1).
Analogously, we can sequentially define h(x) = v(−n)(x)−n{1−v(1)} within all intervals (v(n+1)(1), v(n)(1)]
for n < M which guarantees that
h(u)− h{v(u)} = [v(−(n−1))(u)− (n− 1){1− v(1)}]− [v(−(n−1))(u)− n{1− v(1)}] = 1− v(1)
for all u ∈ (v(n)(1), v(n−1)(1)].
We finally define h(x) = v(−M)(x)−M{1− v(1)} for x ∈ (−∞, v(M)(1)], which guarantees that
h(u)− h{v(u)} = [v(−(M−1))(u)− (M − 1){1− v(1)}]− [v(−M)(v(u))−M{1− v(1)}] = 1− v(1)
for all u ∈ [0, v(M−1)(1)].
This constructed h(·) satisfies h(u)− h{v(u)} = 1− v(1) for all u ∈ R. 2
Lemma 2. Take random variables A and B with invertible CDFs FA(·) and FB(·). Then
FA(y) = FB(y − τ) ∀y ∈ [F−1A (0), F−1A (1)]
is equivalent to
F−1A (p)− F−1B (p) = τ ∀p ∈ [0, 1].
Proof of Lemma A.2. The conclusion follows if we couple A and B through a common
Uniform(0, 1) random variable U : A = F−1A (U) and B = F
−1
B (U). 2
Proof of Theorem 2. Define
f(x) =
{
F1(x) if F
−1
1 (0) ≤ x ≤ F−11 (1)
x− F−11 (0) if x < F−11 (0),
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which is strictly monotonic and continuous. Furthermore, f < F0 everywhere. If F
−1
1 (0) is ∞ then
drop the second piece from the definition. Now, define two new random variables A = f{Y (1)}
and B = f{Y (0)}. Then A ∼ Uniform(0, 1), and the quantile function of B, F−1B (p) = f{F−10 (p)}
is strictly increasing. Now, because for all p ∈ [0, 1]
v(p) ≡ F−1B (p) = f{F−10 (p)} < F0{F−10 (p)} = p,
we can Lemma 1 to obtain h(·) such that
h(p)− h{F−1B (p)} = τ ∀p ∈ [0, 1]
for some τ . We can instead can show that g(y) ≡ h ◦ f(y) is our transform. Define A′ = g(A) and
B′ = g(B). Then F−1A′ = g
(
F−11
)
= h,F−1B′ = g
(
F−10
)
= h{f(F−10 )} = h
(
F−1B
)
, and
F−1A′ (p)− F−1B′ (p) = τ ∀p ∈ [0, 1]
which implies that the CDFs of A′ and B′ are parallel according to Lemma 2. 2
A.2. Testing for Idiosyncratic Variation with Variance Ratios
If Yi(1) and Yi(0) are Normally distributed as N (µ1, σ21) and N (µ0, σ20), then under the null σ21 =
σ20 = σ
2 and the variance ratio tvar = σ̂
2
1/σ̂
2
0, the ratio of sample variances in the two groups,
follows an F distribution. While this conclusion is not generally true for non-Normal distributions,
even asymptotically, we can use higher-order moments to correct this test statistic for non-Normal
outcomes.
Theorem 3. Assume that Y (z) has finite kurtosis κz. Under the null of equal variance,
tkvar ≡ log σ̂
2
1 − log σ̂20√
(κ̂1 − 1) /N1 + (κ̂0 − 1) /N0
d−→ N (0, 1),
as N →∞.
Proof. From the classic result (Lehmann, 1999), we have√
Nt(σ̂
2
t − σ2t ) d−→ N
{
0, var(Yt − µt)2 = σ4(κt − 1)
}
,
and therefore using delta-method we have that√
Nt(log σ̂
2
t − log σ2t ) d−→ N (0, κt − 1).
Under the null, σ21 = σ
2
0, and log σ̂
2
1 − log σ̂20 has the following asymptotic distribution
log σ̂21 − log σ̂20√
(κ1 − 1)/N1 + (κ0 − 1)/N0
d−→ N (0, 1). (A.1)
Due to the fact that κ̂t → κt in probability and Slutsky’s Theorem, we have
log σ̂21 − log σ̂20√
(κ̂1 − 1) /N1 + (κ̂0 − 1) /N0
d−→ N (0, 1).2
Equation A.1 shows that the tvar statistic does not necessarily have an F distribution—the
distribution depends on κ1 and κ2. However, by plugging estimates of these fourth moments in,
we do recover an asymptotically distribution free reference distribution for our statistic. The test
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statistic tkvar essentially replaces the Normality assumption with an assumption of finite fourth
moments, which is often more plausible. This theorem closely follows Box and Andersen (1955),
who use randomization theory to demonstrate that the distribution of the variance ratio depends
on the kurtosis of the underlying outcomes.
A.3. Why the Plug-In for the CDF Approach Fails
As stated in the paper, under the null H0 the CDFs of each group aligned by τ should be the
same. If τ were known, therefore, we could shift the treatment group and compare the resulting
distributions via a Kolmogorov-Smirnov test:
tKS(τ) = max
y
∣∣∣F̂0(y)− F̂1(y + τ)∣∣∣ .
Under the null, we can directly compare this observed test statistic to the null distribution from
the classic, non-parametric KS test. This would be exact.
Unfortunately τ is unknown in practice and is therefore a nuisance parameter. One natural-
seeming approach is to plug in the difference-in-means estimate, τ̂ = µ̂1− µ̂0, yielding the “shifted”
KS (SKS) statistic:
tSKS = max
y
∣∣∣F̂0(y)− F̂1(y + τ̂)∣∣∣ .
Comparing this test statistic to the usual null KS distribution, however, yields invalid p-values. As
Babu and Rao (2004) note, for such tests “the asymptotic null distribution of the test statistic may
depend in a complex way on the unknown parameters.” See also (Van der Vaart, 2000, Theorem
19.23), and the relevant discussion in Koenker and Xiao (2002). We show this more formally in
Theorem 4.
Theorem 4. Let r = limN→∞N1/N , BB(·) be a standard Brownian Bridge, and ξ(·) be a
Gaussian Process with mean function 0 and covariance function cov{ξ(x), ξ(y)} = σ20f0(x)f0(y).
The limiting distribution of the SKS statistic is
√
NtSKS = sup
y
∣∣∣√N {F̂1(y + τ̂)− F̂0(y)} ∣∣∣ d−→ sup
y
∣∣∣ 1√
r
SBB1 +
1√
1− rSBB0
∣∣∣,
where SBB1(·) and SBB0(·) are independent realizations of the shifted Brownian Bridge pro-
cesses: SBB(·) ≡ BB(·) + ξ(·), with covariance structure
cov{BB(x), ξ(y)} = f0(y)F0(x){1−F0(x)} [E{Y (0) | Y (0) ≤ x} − E{Y (0) | Y (0) > x}] .
The correlation between BB(·) and ξ(·) is the “complex dependence” referred to above. Since
the SBB processes depend on F0(y), tSKS also depends on F0(y) and is therefore not distribution
free.
In other words, Theorem 4 demonstrates that “naively” plugging in τ̂ for τ yields a test statistic
with a null distribution that is not the null distribution of the classic KS statistic. Intuitively, if τ is
known, the asymptotic distribution of tKS depends on the sum of two standard Brownian Bridges,
which do not depend on F0(y). The uncertainty in τ̂ changes these from standard Brownian Bridges
to shifted Brownian Bridges, which do depend on F0(y):
√
NtSKS
d−→ sup
y
∣∣∣∣∣
{
1√
r
BB1(y) +
1√
1− rBB0(y)
}
︸ ︷︷ ︸
Standard KS Distribution
+
{
1√
r
ξ1(y) +
1√
1− r ξ0(y)
}
︸ ︷︷ ︸
Additional Shift
∣∣∣∣∣.
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As we show in the simulation studies in Section 6 of the main text, the p-value of this naive
approach can either be inflated or deflated depending on the underlying distribution, F0(y). From
our experience from simulation studies, the naive plug-in approach is conservative for symmetric
distributions such as Normal and t distributions, but it does not yield correct type one error for
skewed distributions such as Exponential and Log-Normal distributions. Table 1 in the main text
illustrates this point.
Proof of Theorem 4. Under the null, the means of the outcomes under treated and control
satisfy µ1 = µ0 + τ , the variances are the same σ
2
1 = σ
2
0 = σ
2, and corresponding PDFs then satisfy
f1(y + τ) = f0(y). First, we have
√
N(τ̂ − τ) = 1√
r
1√
N1
N1∑
i=1
{Yi(1)− µ1} − 1√
1− r
1√
N0
N∑
i=N1+1
{Yi(0)− µ0}.
The difference between the shifted empirical CDFs is
√
N
{
F̂1(y + τ̂)− F̂0(y)
}
=
√
N
{
F̂1(y + τ)− F̂0(y)
}
+
√
N {F1(y + τ̂)− F1(y + τ)}
+
√
N
[{
F̂1(y + τ̂)− F1(y + τ̂)
}
−
{
F̂1(y + τ)− F1(y + τ)
}]
=
√
N
{
F̂1(y + τ)− F̂0(y)
}
+
√
N {F1(y + τ̂)− F1(y + τ)}+ oP (1),
where the last equality is due to the stochastic equicontinuity of the indicator function. By definition
of the empirical CDFs, we have
√
N
{
F̂1(y + τ̂)− F̂0(y)
}
=
1√
r
1√
N1
N1∑
i=1
[I{Yi(1) ≤ y + τ} − F1(y + τ)]− 1√
1− r
1√
N0
N∑
i=N1+1
[I{Yi(0) ≤ y} − F0(y)]
+f0(y)
√
N(τ̂ − τ) + oP (1)
=
1√
r
1√
N1
N1∑
i=1
[I{Yi(1) ≤ y + τ} − F1(y + τ)]− 1√
1− r
1√
N0
N∑
i=N1+1
[I{Yi(0) ≤ y} − F0(y)]
+f0(y)
[
1√
r
1√
N1
N1∑
i=1
{Yi(1)− µ1} − 1√
1− r
1√
N0
N∑
i=N1+1
{Yi(0)− µ0}
]
+ oP (1).
Since both
1√
N1
N1∑
i=1
[I{Yi(1) ≤ y + τ} − F1(y + τ) + f0(y){Yi(1)− µ1}]
and
1√
N0
N∑
i=N1+1
[I{Yi(0) ≤ y} − F0(y) + f0(y){Yi(0)− µ0}]
have the same asymptotic distribution as SBB defined in Theorem 4, we have
√
N
{
F̂1(y + τ̂)− F̂0(y)
}
d−→ 1√
r
SBB1(y)− 1√
1− rSBB0(y).
The final conclusion follows from the symmetry of the shifted Brownian Bridge. 2
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A.4. Proposition 1 for the FRT-CI Method
Proposition 2. Given that CIγ is a (1−γ)-level confidence interval for τ , pγ is a valid p-value,
in the sense that Pr(pγ ≤ α) ≤ α under the null.
Proof of Proposition 1. The validity of the FRT-CI p-value is fairly immediate accord-
ing to Berger and Boos (1994). First, the valid confidence interval guarantees Pr(τ0 6∈ CIγ) ≤
γ. Second, given the true value of τ0, randomization test yields a valid p-value, which implies
Pr {p(τ0) ≤ α− γ} ≤ α − γ. Third, given the fact that τ0 ∈ CIγ , the supremum of p-values over
CIγ , supτ∈CIγ p(τ), is greater than or equal to p(τ0). These ingredients give us
Pr(pγ ≤ α) = Pr(pγ ≤ α, τ0 ∈ CIγ) + Pr(pγ ≤ α, τ0 6∈ CIγ)
≤ Pr
{
sup
τ∈CIγ
p(τ) ≤ α− γ, τ0 ∈ CIγ
}
+ Pr(τ0 6∈ CIγ)
≤ Pr {p(τ0) ≤ α− γ, τ0 ∈ CIγ}+ γ
≤ Pr {p(τ0) ≤ α− γ}+ γ
≤ α− γ + γ = α.2
